Coya Therapeutics In Catbird Seat Following Dr. Reddy’s Licensing Deal
Carol Hamilton/iStock via Getty Images Since I first wrote about Coya Therapeutics (NASDAQ:COYA), the company has strengthened its strategic positioning with a strong licensing deal with Dr. Reddy’s, the company Coya previously in-licensed from its biosimilar CTLA4-Ig, Abatacept, which is one component of COYA 302, Coya’s lead combination therapy for ALS and potentially other diseases….
